このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Perrigo マネジメント

マネジメント基準チェック /34

Perrigo'sの CEO はPatrick Lockwood-Taylorで、 Jun2023年に任命され、の在任期間は 1.17年です。の年間総報酬は$ 6.67Mで、 9.1%給与と90.9%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.033%を直接所有しており、その価値は$ 1.26M 。経営陣と取締役会の平均在任期間はそれぞれ6.5年と5.7年です。

主要情報

Patrick Lockwood-Taylor

最高経営責任者

US$6.7m

報酬総額

CEO給与比率	9.1%
CEO在任期間	1.3yrs
CEOの所有権	0.03%
経営陣の平均在職期間	2.3yrs
取締役会の平均在任期間	5.8yrs

経営陣の近況

Recent updates

Improved Revenues Required Before Perrigo Company plc (NYSE:PRGO) Shares Find Their Feet

Jul 03

These 4 Measures Indicate That Perrigo (NYSE:PRGO) Is Using Debt Extensively

May 29

Benign Growth For Perrigo Company plc (NYSE:PRGO) Underpins Its Share Price

Mar 27

These 4 Measures Indicate That Perrigo (NYSE:PRGO) Is Using Debt Extensively

Feb 01

The Market Doesn't Like What It Sees From Perrigo Company plc's (NYSE:PRGO) Revenues Yet

Dec 28

Perrigo's New Chapter: Its Bold Turnaround Plan Is Worth Buying

Nov 15

The Prognosis For Perrigo

Aug 30

Perrigo Outlook Healed By Repositioning

Jun 12

Perrigo raises dividend by 5% to $0.273/share

Feb 21

Perrigo: Still Languishing But Short-Term Trend Offers Encouragement

Jan 18

Perrigo Non-GAAP EPS of $0.56 misses by $0.11, revenue of $1.1B misses by $40M, lowers FY adj. EPS guidance

Nov 08

Perrigo to invest $170M to expand baby formula manufacturing, buys Nestlé Gateway plant

Nov 01

Perrigo Company plc Is Back On Track

Oct 20

Perrigo to face FDA AdCom meeting for OTC contraceptive

Sep 12

Perrigo responds to 'misleading and inaccurate information' on Zantac claims

Aug 17

Perrigo reports Q2 mixed results; raises FY22 organic net sales growth outlook

Aug 09

Perrigo declares $0.26 dividend

Aug 02

Perrigo: HRA Acquisition To Drive Significant Growth

Jul 20

Perrigo unit seeks FDA over-the-counter approval for birth control pill Opill

Jul 11

Perrigo: The Longer The Base The Higher In Space

Apr 12

CEO報酬分析

Perrigo の収益と比較して、Patrick Lockwood-Taylor の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 29 2024	n/a	n/a	-US$114m
Mar 30 2024	n/a	n/a	US$800k
Dec 31 2023	US$7m	US$605k	-US$4m

報酬と市場: Patrickの総報酬 ($USD 6.67M ) は、 US市場 ($USD 6.76M ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Patrickの報酬と会社の業績を比較するにはデータが不十分です。

CEO（最高経営責任者

Patrick Lockwood-Taylor

1.3yrs

在職期間

US$6,672,584

報酬

Mr. Patrick Lockwood-Taylor has been President, Chief Executive Officer and Director at Perrigo Company plc since June 30, 2023. He had been Regional President and Head North American Consumer Health Busin...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Patrick Lockwood-Taylor	President	1.3yrs	US$6.67m	0.033% $ 1.2m
Eduardo Bezerra	Executive VP & CFO	2.3yrs	US$3.05m	0.011% $ 396.1k
Ronald Janish	Chief Transformation Officer and Executive VP of Global Operations & Supply Chain	8.9yrs	US$2.23m	0.019% $ 655.2k
Svend Andersen	Advisor	7.6yrs	US$2.55m	0.059% $ 2.1m
Kyle Hanson	Advisor	no data	US$2.28m	0.0082% $ 285.3k
Shannon Hukill	Senior Director of Technical Operations	13yrs	データなし	データなし
Alison Ives	Executive VP & Chief Scientific Officer	2.3yrs	データなし	0.014% $ 473.1k
Bradley Joseph	Vice President of Global Investor Relations & Corporate Communications	no data	データなし	データなし
Charles Atkinson	Executive VP	no data	データなし	データなし
Mary Reilly-Brest	Director of Global Organizational and Human Resource Development	16.7yrs	データなし	データなし
Robert Willis	Chief Human Resources Officer & Executive VP	5.5yrs	データなし	0.023% $ 806.6k
Catherine C. Schmelter	Executive VP and President of Consumer Self-Care Americas & Global Portfolio Optimization	less than a year	データなし	データなし

2.3yrs

平均在職期間

55yo

平均年齢

経験豊富な経営陣: PRGOの経営陣は経験豊富であると考えられます ( 3.9年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Patrick Lockwood-Taylor	President	1.3yrs	US$6.67m	0.033% $ 1.2m
Jeffrey Kindler	Independent Director	7.6yrs	US$399.99k	0.017% $ 589.8k
Donal O'Connor	Independent Director	9.8yrs	US$405.30k	0.020% $ 683.9k
Bradley Alford	Independent Director	7.6yrs	US$387.49k	0.026% $ 923.0k
Albert Manzone	Independent Director	2.2yrs	US$387.49k	0.0054% $ 189.9k
Orlando Ashford	Independent Chairman of the Board	3.8yrs	US$532.99k	0.012% $ 403.1k
Julia Brown	Director	less than a year	US$12.53k	データなし
Geoffrey Parker	Independent Director	7.8yrs	US$387.49k	0.038% $ 1.3m
Adriana Karaboutis	Independent Director	7.3yrs	US$390.99k	0.016% $ 576.2k
Katherine Doyle	Independent Director	4.2yrs	US$392.80k	0.0044% $ 153.8k

5.8yrs

平均在職期間

60yo

平均年齢

経験豊富なボード: PRGOの取締役会は経験豊富であると考えられます ( 5.7年の平均在任期間)。

Perrigo マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Perrigo Company plc Appoints Charles Atkinson, as Executive Vice President, General Counsel and Secretary

Advisor recently sold US$969k worth of stock

Perrigo Company plc Appoints David Ball as Executive Vice President and Chief Brand and Digital Officer

President exercised options to buy US$477k worth of stock.

Perrigo Company plc Appoints Todd Penegor as Member of Board and to Serve on Audit Committee, Effective June 21, 2024

Perrigo Company plc Announces Executive Changes

Recent updates

Perrigo Company plc Appoints Charles Atkinson, as Executive Vice President, General Counsel and Secretary

Upcoming dividend of US$0.28 per share

Advisor recently sold US$969k worth of stock

Perrigo (NYSE:PRGO) Is Due To Pay A Dividend Of $0.276

Perrigo Company plc Appoints David Ball as Executive Vice President and Chief Brand and Digital Officer

The Play On Perrigo

Perrigo (NYSE:PRGO) Has Announced A Dividend Of $0.276

Second quarter dividend of US$0.28 announced

Second quarter 2024 earnings released: US$0.77 loss per share (vs US$0.066 profit in 2Q 2023)

Perrigo Company plc Reports Impairment Charges for the Second Quarter Ended June 29, 2024

Perrigo Company plc to Report Q2, 2024 Results on Aug 02, 2024

President exercised options to buy US$477k worth of stock.

Esteve Healthcare S.L. completed the acquisition of HRA Pharma Rare Diseases America, LLC from Perrigo Company plc.

Improved Revenues Required Before Perrigo Company plc (NYSE:PRGO) Shares Find Their Feet

Perrigo Company plc Appoints Todd Penegor as Member of Board and to Serve on Audit Committee, Effective June 21, 2024

Perrigo Company plc Announces Executive Changes

These 4 Measures Indicate That Perrigo (NYSE:PRGO) Is Using Debt Extensively

Upcoming dividend of US$0.28 per share

Consensus EPS estimates fall by 288%

Perrigo Company plc Reaffirms Earnings Guidance for 2024

New major risk - Financial position

First quarter 2024 earnings released: EPS: US$0.03 (vs US$0.008 loss in 1Q 2023)

Fourth quarter dividend of US$0.28 announced

Perrigo Company plc Announces Quarterly Dividend, Payable on June 18, 2024

Esteve Healthcare S.L. agreed to acquire HRA Pharma Rare Diseases America, LLC from Perrigo Company plc (NYSE:PRGO) for approximately €280 million.

Perrigo Company plc to Report Q1, 2024 Results on May 07, 2024

Benign Growth For Perrigo Company plc (NYSE:PRGO) Underpins Its Share Price

Perrigo Company plc, Annual General Meeting, May 02, 2024

Perrigo Company plc Announces Erica L. Mann Not to Stand for Re-Election to its Board of Directors

Consensus EPS estimates have been downgraded.

Full year 2023 earnings: EPS misses analyst expectations

Perrigo Company plc Reports Impairment Charges for the Fourth Quarter Ended December 31, 2023

Price target decreased by 13% to US$38.75

Consensus EPS estimates fall by 24%

Perrigo Company plc Increases its Quarterly Dividend, Payable on March 26, 2024

Perrigo Company plc to Report Q4, 2023 Results on Feb 27, 2024

These 4 Measures Indicate That Perrigo (NYSE:PRGO) Is Using Debt Extensively

The Market Doesn't Like What It Sees From Perrigo Company plc's (NYSE:PRGO) Revenues Yet

Upcoming dividend of US$0.27 per share at 3.6% yield

President recently bought US$319k worth of stock

Perrigo's New Chapter: Its Bold Turnaround Plan Is Worth Buying

Perrigo Company plc Updates Earnings Guidance for the Fiscal 2023

Perrigo Company plc to Report Q3, 2023 Results on Nov 07, 2023

Perrigo Company plc Announces Executive Changes

The Prognosis For Perrigo

Perrigo Company plc Reaffirms Earnings Guidance for the Fiscal 2023

Perrigo Company plc to Report Q2, 2023 Results on Aug 08, 2023

Perrigo Company plc Announces U.S. FDA Approval for Opill OTC Daily Oral Contraceptive

Perrigo Outlook Healed By Repositioning

Perrigo Company plc Appoints Patrick Lockwood-Taylor as Its New Chief Executive Officer

Perrigo Announces U.S. FDA Approval for Nicotine Coated Mint Lozenge

Perrigo Company plc Announces FDA Approval of Opill®? for Over-The-Counter Use

Perrigo Company plc Reaffirms Sales Guidance for the Fiscal Year 2023

Perrigo Announces Quarterly Dividend, Payable on June 20, 2023

Perrigo raises dividend by 5% to $0.273/share

Perrigo Company plc to Report Q4, 2022 Results on Feb 27, 2023

Theodore R. Samuels Not to Stand for Re-Election to the Perrigo Company plc's Board of Directors

Perrigo: Still Languishing But Short-Term Trend Offers Encouragement

Perrigo Company plc Provides Earnings Guidance for the Fiscal Year 2022

Perrigo Non-GAAP EPS of $0.56 misses by $0.11, revenue of $1.1B misses by $40M, lowers FY adj. EPS guidance

Perrigo Company plc Announces Quarterly Dividend, Payable on December 20, 2022

Perrigo Company plc (NYSE:PRGO) acquired Good Start Packaging, Inc. from Nestle Canada Inc.

Perrigo to invest $170M to expand baby formula manufacturing, buys Nestlé Gateway plant

Perrigo Company plc to Report Q3, 2022 Results on Nov 08, 2022

Perrigo Company plc Is Back On Track

Perrigo to face FDA AdCom meeting for OTC contraceptive

Perrigo Company plc Announces Litigation Update

Perrigo responds to 'misleading and inaccurate information' on Zantac claims

Perrigo Company Revised Earnings Guidance for the Full Year of 2022

マネジメント基準チェック /34